Nebivolol Pentafarma (Nebivolol Hydrochloride)

Nebivolol is indicated for conditions within the cardiovascular disease pathway, primarily targeting blood pressure regulation and cardiac function.

• Hypertension: reduces systolic and diastolic blood pressure, helping achieve target levels.
• Heart failure: improves left ventricular ejection fraction and lessens symptoms such as dyspnea and fatigue.
• Elderly patients with hypertension: provides effective blood pressure control with a favorable tolerability profile.

• Nebivolol acts as a selective β1‑adrenergic receptor antagonist, decreasing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric‑oxide synthase, increasing nitric‑oxide release, which causes vasodilation and lowers peripheral vascular resistance, contributing to its antihypertensive and heart‑failure benefits.

Nebivolol may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: general tiredness that may improve with continued use.
• Nasal congestion: blockage or runny nose.

Serious or Rare Side Effects

• Severe bradycardia: markedly slow heart rate requiring medical attention.
• Symptomatic hypotension: significant drop in blood pressure causing faintness.
• Heart block: impairment of electrical conduction in the heart.
• Bronchospasm: narrowing of airways, particularly in patients with asthma or COPD.
• Allergic reactions: rash, itching, or swelling that may indicate hypersensitivity.
• Hepatic injury: abnormal liver function tests or jaundice.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

• Blood pressure monitoring: check regularly to ensure therapeutic targets are met.
• Heart rate assessment: observe for excessive bradycardia, especially in patients with conduction disorders.
• Respiratory caution: use carefully in patients with asthma or chronic obstructive pulmonary disease.
• Hepatic/renal function: adjust therapy if significant impairment is present.
• Discontinuation: avoid abrupt cessation; taper gradually to reduce rebound hypertension.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebivolol can interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Other beta‑blockers: additive cardiac depression may lead to severe bradycardia.
• Non‑dihydropyridine calcium channel blockers (verapamil, diltiazem): increased risk of AV‑block and heart failure.
• Clonidine withdrawal: abrupt discontinuation can cause hypertensive crisis.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise nebivolol plasma concentrations.
• Antihypertensive agents (ACE inhibitors, diuretics): monitor for excessive blood pressure lowering.
• Antidiabetic drugs: nebivolol may mask hypoglycemia symptoms; adjust monitoring accordingly.